Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GMAB) Liabilities and Shareholders Equity: 2018-2020

Historic Liabilities and Shareholders Equity for Genmab A (GMAB) over the last 3 years, with Dec 2020 value amounting to $2.4 billion.

  • Genmab A's Liabilities and Shareholders Equity rose 25.01% to $2,670 in Q2 2021 from the same period last year, while for Jun 2021 it was $4.0 billion, marking a year-over-year increase of 15.64%. This contributed to the annual value of $2.4 billion for FY2020, which is 55.39% up from last year.
  • Genmab A's Liabilities and Shareholders Equity amounted to $2.4 billion in FY2020, which was up 55.39% from $1.6 billion recorded in FY2019.
  • In the past 5 years, Genmab A's Liabilities and Shareholders Equity ranged from a high of $2.4 billion in FY2020 and a low of $935.5 million during FY2018.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.6 billion, with a median of $1.6 billion in 2019.
  • Data for Genmab A's Liabilities and Shareholders Equity shows a peak YoY skyrocketed of 66.88% (in 2019) over the last 5 years.
  • Yearly analysis of 3 years shows Genmab A's Liabilities and Shareholders Equity stood at $935.5 million in 2018, then spiked by 66.88% to $1.6 billion in 2019, then skyrocketed by 55.39% to $2.4 billion in 2020.